Abstract: Compositions and methods for treating infectious disease. The composition includes a particle selected from the group consisting of liposome, extracellular vesicle, solid lipid nanoparticles, and polymeric nanoparticles; a miRNA; and an antibiotic, wherein the particle is loaded with at least one of the miRNA and the antibiotic.

Abstract: The present disclosure provides a therapeutic method comprised of targeting the tumor-associated antigen, Lactate Dehydrogenase C (LDHC), in LDHC-expressing cancers or tumors. This novel approach offers a highly specific cancer treatment with little or no off-target effects. Targeting LDHC with the use of silencing molecules increases tumor cell death by inducing excess DNA damage, and more importantly, can render breast tumor cells more responsive to non-specific, DNA damaging drugs and DNA damage repair inhibitors, such as platinum-based alkylating agents (e.g. cisplatin) and Poly ADP-Ribose Polymerase (PARP) inhibitors (e.g. olaparib). Targeting LDHC in tumor cells has the potential to specifically sensitize tumor cells to these drugs and/or inhibitors, leading to enhanced tumor cell killing and potentially minimizing side effects.

Abstract: The invention relates to a composition and method to increase survival of fish following catch-and-release events. The composition comprises an energy substrate and a hydrocolloid. The composition may comprise an application-safe buffer. The energy substrate may be a glycolysis metabolite, a Krebs cycle metabolite, an amino acid, a nitric oxide donor, a triglyceride, and mixtures thereof. The hydrocolloid may be a polysaccharide. The composition may include an oxygenated substrate, a trophic hormone, a stress reducing additive, a chelating agent, an antimicrobial preservative, and a color additive, and mixtures thereof. The method comprises after catching the fish, applying the composition to the fish and releasing the fish back into the wild. The composition may alternatively be mixed with a flotant or a cured polymer in the shape of a lure such that composition may be dispersed onto the oxygen exchange tissue of the fish when it is caught.

Abstract: A method of manufacturing a high molecular weight heparin (HMWH) compound is disclosed. The method comprises dissolving heparin to form a heparin solution and fractionating the heparin solution via tangential flow filtration (TFF) using a membrane with a molecular weight cut off (MWCO) between about 8 kDa and about 12 kDa. The TFF yields a retentate comprising fractionated heparin with a weight average molecular weight of about 20 kDa or greater, i.e., a high molecular weight heparin compound. A substantial proportion of heparin chains in the fractionated heparin may have a high molecular weight, e.g., 50% of the heparin chains or greater may have a molecular weight of 20 kDa or greater.

Abstract: The present invention provides methods of preventing or treating coronavirus infection and reducing coronavirus infection rate in vitro with antiviral composition comprising poly(3,4-ethylenedioxythiophene):poly(styrene sulfonate) (PEDOT:PSS), wherein the PEDOT:PSS is selected from PEDOT:PSS aqueous solutions in various formulas. Specifically, the molar ratio of PEDOT to PSS in the PEDOT:PSS aqueous solution in the antiviral composition may be 1:1.5 to 1:6 and the resistivity of the PEDOT:PSS aqueous solution in the antiviral composition may be 100 ?/sq to 5×107 ?/sq. The antiviral composition is used to inhibit the binding between the spike protein of the coronavirus and the host cells with angiotensin-converting enzyme 2 (ACE2) on surface. The coronavirus may be SARS-CoV-2.

Abstract: Wound-care composition and method of use. The composition comprises: a substrate; potassium alum; and urea. The potassium alum makes up 10.27 wt. % of the composition within a tolerance of +/- 50%; and the urea makes up 0.12 wt. % of the composition within a tolerance of +/- 50%. The method comprises applying the composition to a wound on a non-human animal.

Abstract: The present subject matter provides a series of multifunctional anti-inflammatory agents comprising tannic acid, Zn2+, and different amounts of gentamicin (TA-Zn-Gen NPs) to effectively improve sepsis treatment through five modes of anti-sepsis activity: (1) bound cfDNA with high affinity and inhibited cfDNA-induced activation of TLRs and nuclear factor kappa B (NF-?B) signaling; (2) inhibited activated macrophage-induced macrophage recruitment; (3) scavenged ROS and reduced ROS-induced DNA damage and cell death; (4) inhibited NO production induced by bacterial LPS; and (5) provided potent antibacterial activity.

Abstract: A stye treatment formulation that includes a colloidal silver concentrate, an arnica extract, a calendula extract, niacinamide, and at least one carrier fluid is described. Methods of using the stye treatment formulation to treat at least one patient in need thereof are also described.

Abstract: The present invention is directed to a method and a composition for producing and using a plant-based biocidal solution. The plant-based biocidal solution contains a bioactive material and a plant-based substance formed from the cellular material of a plant. The plant-based substance is capable of binding to the bioactive material. In some embodiments, the bioactive material is hydrogen peroxide. The hydrogen peroxide can be added exogenously or generated endogenously. In accordance with further embodiments, the plant-based biocidal solution can be applied to a target, thereby impairing the target. In some embodiments, the target can be a pathogen. In accordance with another embodiment, the plant-based substance of the plant-based biocidal solution can form a microscopic cluster, a complex, or an aggregate for providing sufficient bioactive material to overcome the defense mechanism of the target.

Abstract: The present disclosure pertains to immune cells comprising exogenous fibrolytic agents and/or exogenous anti-inflammatory agents and methods of using immune cells comprising exogenous fibrolytic agents and/or exogenous anti-inflammatory agents.

Abstract: The present disclosure relates to a composition including non-autologous plasma or serum and a polymer; method of treating ophthalmic diseases (e.g., dry eye syndrome) or moisturizing and/or repairing non-keratinized surfaces including nonhealing wounds with a composition including non-autologous plasma or serum and a polymer; and a therapeutic agent delivery device for delivery of the composition to the eye or a non-keratinized surface of a subject.

Abstract: The present disclosure provides a chimeric polypeptide comprising at least one heterologous nuclear export signal linked to an adaptor protein of a receptor. The adaptor protein may be a Linker for Activation of T cell (LAT). The receptor may comprise a chimeric receptor.

Abstract: A sterilised platelet lysate obtained with a method for sterilising a platelet lysate in the liquid state comprising at least the endogenous growth factors TGF-beta 1, EGF, PDGF-AB, IGF-1, VEGF and bFGF. The method comprising freezing the liquid platelet lysate in order to obtain a frozen platelet lysate, and irradiating the frozen platelet lysate with ionising radiation in order to obtain a sterilised platelet lysate, the irradiation being adapted so as to preserve at least 80% of the concentration of at least one of the endogenous growth factors chosen from the group consisting of TGF-beta 1, EGF, PDGF-AB, IGF-1 and VEGF.

Abstract: The present invention relates to a novel use of milk exosomes, and more specifically, provides a method of inhibiting UV-induced oxidative damage of cells using an effective amount of exosomes isolated from milk or goat milk.

Abstract: Embodiments disclosed here provide engineered modified hematopoietic stem cells (HSCs), artificially prostaglandin E2 (PGE2)-stimulated HSCs, compositions comprising these HSCs, methods of using these modified HSCs for treating autoimmune diseases and disorders and for suppressing the immune system. In particular, the engineered modified HSCs or PGE2-stimulated HSCs express the surface marker, programmed cell death-1 ligand 1 (PD-L1).

Abstract: A cytokine storm suppressor containing microparticles derived from a culture supernatant of dental pulp-derived stem cells, adipose-derived stem cells, bone marrow-derived stem cells, umbilical cord-derived stem cells or immortalized stem cells thereof in which the microparticles contain extracellular superoxide dismutase (SOD3) in an effective amount capable of repairing a tissue or a cell damaged by a cytokine storm or a higher amount and which is used for administration to a human or a nonhuman animal with a cytokine storm before damage of a tissue is caused by the cytokine storm to suppress the tissue damage by the cytokine storm through suppression of the cytokine storm or used for administration to a human or a nonhuman animal with damage of a tissue caused by a cytokine storm to repair the tissue damaged by the cytokine storm through suppression of the cytokine storm; a method for using the cytokine storm suppressor; and a screening method.

Abstract: The present invention relates to a method of manufacturing an animal cartilage-derived injectable composition, an injectable composition manufactured by the method, and a use thereof. The injectable composition of the present invention includes a collagen-containing biomaterial in a formulation injectable into joint cavity and may induce cartilage tissue regeneration by repairing tissue via direct injection to a target region without surgical incision. In addition, the injectable composition may be used as a therapeutic agent for arthritis by alleviating osteoarthritis not only because the animal cartilage-derived extracellular matrix contained in the injectable composition protects articular cartilage tissue but also because an environment capable of regenerating damaged articular tissue is created by inducing differentiation of intra-articular stem cells into chondrocytes.

Abstract: Embodiments of the disclosure include means of treating a variety of periodontal and dental diseases using fibroblasts, modified fibroblasts, and derivatives thereof. In one embodiment, the disclosure encompasses the utilization of fibroblasts for treatment of gum disease. In another embodiment, disclosed are means of utilizing fibroblasts and modifications thereof, for preparing gum tissue for placement of an artificial tooth. In another embodiment, fibroblasts are utilized to increase efficacy of bone grafts. In other embodiments, fibroblasts are utilized to generate artificial teeth through utilization of various scaffolding and/or 3 dimensional printing means.

Abstract: A cell-free fat extract may be used for treating osteoporosis. Specifically, the cell-free fat extract can be used to prepare a composition or preparation for preventing and/or treating osteoporosis, in particular osteoporosis due to estrogenic decline. The cell-free fat extract inhibits osteoblast differentiation and osteoclast differentiation, inhibits fusion of the bone marrow macrophage skeleton, improves the structure of hind limb bone, alleviates bone loss and attenuate bone resorption, and improves the mechanical properties of the femur.

Abstract: A cell preparation that can suppress muscle mass loss. A cell preparation for use in suppressing muscle mass loss includes: umbilical cord-derived cells.

Abstract: There is disclosed a composition for protection against pathogens, the composition comprising: predetermined amount of at least one type of plant-derived oil; predetermined amount of extracts from shea tree; predetermined amount of extracts from aloe vera; predetermined amount of wax; predetermined amount of chitosan; wherein the composition is in a form suitable to be applied to intranasal cavity. A method is disclosed herein.

Abstract: Disclosed herein are methods of terminally sterilizing bacterial minicells or compositions comprising bacterial minicells by exposure to ionizing irradiation. Also disclosed are terminally sterilized bacterial minicells, pharmaceutical compositions comprising the bacterial minicells, and methods of using the bacterial minicells and pharmaceutical compositions.

Abstract: An Akkermansia muciniphila AK32 (Accession No. KCTC 14172BP) strain. The Akkermansia muciniphila AK32 strain prevents or improves intestinal damage. A method for preventing, improving or treating intestinal damage, including administering to a subject an effective amount of the Akkermansia muciniphila AK32 strain or a culture thereof as an active ingredient.

Abstract: A composition comprising microcapsules in an oral dosage form is described. The oral dosage form comprises gastric-resistant ileal-sensitive microcapsules comprising a matrix and active agent such as probiotic bacterium, contained within the matrix, in which the matrix comprises denatured whey protein, and in which the microcapsules are be coldgelated and vacuum dried microcapsules, and thus are subject to less heat treatment than conventional probiotic-containing microparticles. The microcapsules may be formed by extrusion through a single or double nozzle and are vacuum dried to a water activity (Aw) of 0.30 or less. The microcapsules may be subjected to two separate vacuum drying steps to further reduce the water activity and provide microcapsules with greater stability against moisture, humidity and thermal processes such as pasteurisation and Ultra High Temperatures (i.e.

Abstract: The invention relates to direct-fed microbials for use in E. coli inhibition in animals in combination with antibiotics selected from the group consisting of ceftiofur, oxytetracycline, tulathromycin, and lincomycin. More particularly, the invention relates to isolated Bacillus strains 2, 3, 4, 5, 9, 57, 71, and 126, and strains having all of the identifying characteristics of these strains, for a use comprising the above-mentioned use.

Abstract: The present invention relates to a composition for preventing or treating Clostridium difficile infection, comprising at least one from the group consisting of cells, cultures, lysates, and extracts of Clostridium scindens, Blautia producta, and Enterococcus faecium.

Abstract: Methods and materials for intrathecal delivery of recombinant Adeno-associated virus 9 (rAAV9) encoding Methyl-CpG binding protein 2 (MECP2) are provided. Use of the methods and materials is contemplated, for example, for the treatment of Rett syndrome.

Abstract: The present invention provides a medicament for treating cancer comprising, as an active ingredient, an apolipoprotein and/or interferon regulatory factor 7 (IRF7), wherein the expression of the apolipoprotein and IRF7 is increased in cancer cells by treatment of the cancer cells with hemagglutinating virus of Japan-envelope (HVJ-E); the medicament for treating cancer used in combination with a T-cell co-stimulator agonist; and an immunostimulant comprising a combination of a T-cell co-stimulator agonist and at least one selected from the group consisting of an apolipoprotein, IRF7 and HVJ-E.

Abstract: The present invention resides in the discovery that altered abundance of fungal species in the gut and feces of both fecal microbiota transplantation (FMT) donors and recipients may influence the outcome of FMT treatment. Thus, novel methods are provided for identifying subjects as suitable donor or recipients for FMT, for assessing the likelihood of FMT treatment success, and for enhancing FMT treatment efficacy. Also provided are kits and compositions for FMT with enhanced efficacy.

Abstract: Compositions and methods are provided for the treatment of a variety of cancers. The compositions generally comprise at least one edible or medicinal mushroom or extract thereof, at least one cannabinoid, at least one terpene, and at least one flavonoid. Methods for optimizing compositions using artificial intelligence algorithms are also provided.

Abstract: An enhanced food composition in the form of a frozen or refrigerated food is described, the enhanced food composition comprising a nitrate-containing vegetable, such as beetroot, effectively mixed with a salt content of a food component of the food composition at a specified ratio. The enhanced food composition has the effect to prevent an increase in blood pressure while masking the bad taste of the nitrate-containing vegetable.

Abstract: Disclosed is a method for moisturizing skin in need thereof, the method comprising topically applying to the skin a composition that includes effective amounts of an extract from Echinacea purpurea, an extract from Silybum marianum, and glycerin, wherein topical application of the composition activates human cannabinoid receptor type 2 and inhibits fatty acid amide hydrolase activity in the skin and treats the skin.

Abstract: The present application relates to an anti-coccidial composition comprising mangosteen, and the uses thereof. The composition comprising mangosteen according to an example has excellent effect of directly killing protozoa which can induce coccidiosis, effect of inhibiting cell penetration by protozoa and/or effect of inhibiting intracellular protozoan proliferation, and has excellent in vivo coccidiosis prevention, relief and therapeutic effects.

Abstract: A traditional Chinese medicine composition for treating hand-foot syndrome after targeted drug treatment is mainly prepared from the following components by weight: 20-50 parts of Radix Sophorae Flavescentis, 20-50 parts of Herba Taraxaci, 20-50 parts of Flos Chrysanthemi Indici, and 20-50 parts of Herba Cum Radice Violae Yedoensitis, 20-50 parts of Rhizoma Smilacis Glabrae, 30-60 parts of Radix Astragali Seu Hedysari, 10-35 parts of Kochia scoparia (L.) Schrad, 10-45 parts of Carthamus tinctorius L., 15-45 parts of Cortex Radicis Dictamni Dasycarpi, 5-15 parts of Herba Ephedrae, 5-25 parts of Angelica sinensis, 5-25 parts of Rhizoma Ligustici Chuangxiong, 10-30 parts of Radix Rehmanniae, 5-15 parts of Ramulus cinnamomi, 10-30 parts of Cynanchum otophyllum Schneid, 5-15 parts of Semen Sinapis Albae, 5-20 parts of Arisaema heterophyllum Blume, 5-20 parts of Typhonium blumei Nicolson & Sivadasan, and 10-40 parts of Radix Glycyrrhizae.

Abstract: The invention relates to methods of evaluating the quality of a batch of an herbal composition, the method comprising subjecting a test batch of the herbal composition to one or more biological analysis methods and comparing the results derived from the test batch to the results of a known batch of herbal composition which has a known in vivo effect.

Abstract: Embodiments of the present disclosure include compositions and methods for treating type 2 diabetes using anti-diabetic steroidal lactones of Withania Coagulans, such as Coagulansin A and derivatives and analogues thereof are described. For example, a method of treating type 2 diabetes in a subject in need thereof, the method comprising administering a therapeutically effective amount of Coagulansin A or a derivative or analogue thereof to the subject is provided. Further described embodiments include compositions and methods of treating muscle atrophy in a subject with type 2 diabetes by initiating regeneration of diseased skeletal muscle myoblasts using anti-diabetic steroidal lactones of Withania Coagulans.

Abstract: A method of topically applying to skin a composition comprising a water soluble Phoenix dactylifera seed extract, an essential oil from the leaves of tea tree, an aqueous Myrothamnus flabellifolia leaf and stem extract, and a saccharide isomerate comprising an exopolysaccharide of Vibrio alginolyticus is disclosed.

Abstract: Disclosed are compositions and methods for treating or ameliorating the symptoms of cancer (e.g., oral cancer) by using a poly-pharmaceutical drug, whose composition consists of relationally optimized ratios of bioactive compounds to enhance their pharmacological characteristics.

Abstract: The present invention relates to N-acyl amino acid products and their use in diagnosing and treating disease.

Abstract: The present invention related to a composition for the prevention, improvement or treatment of allergic diseases or itching.

Abstract: The technology described herein is directed to compositions comprising components of multi-component CALs or CARs, e.g., a TCR recognition domain; and one or both of: (a) an intracellular signaling domain; and (b) a first-type protein interaction domain. Further provided herein are methods for treating or preventing an autoimmune disease, a transplant rejection, or graft versus host disease.

Abstract: Polypeptides comprising a C3b binding region are disclosed, as well as nucleic acids and vectors encoding such polypeptides, and cells and compositions comprising such polypeptides. Also disclosed are uses and methods using the polypeptides for treating and preventing diseases and conditions.

Abstract: A method for treatment of Type-1 diabetes includes the steps of administering manganin II peptide consisting of the amino acid sequence of SEQ ID 1 and administering recombinant human growth hormone.

Abstract: The disclosure provides, in various embodiments, methods of treating fungal infections in subjects in need thereof, methods of attenuating virulence of fungi (e.g., in subjects in need thereof), and methods of inhibiting formation of fungal biofilms on surfaces (e.g., living or inert surfaces) with mucin glycans, tautomer, stereoisomer and/or pharmaceutically acceptable salts thereof. The disclosure further provides, in various embodiments, mucin glycan compositions, such as synthetic mucin glycans and defined mucin glycan compositions.

Abstract: The present invention relates to octopromycin, which is a synthetic peptide having excellent antibacterial activity against Acinetobacter sp. bacteria, and an antibacterial composition comprising the octopromycin as an active ingredient. Octopromycin or a fragment thereof according to the present invention exhibits high inhibitory effects on the growth and biofilm formation of Acinetobacter baumannii, which is a multi-drug resistant bacterium causing nosocomial infection, in addition to being free of cytotoxicity, thus finding advantageous applications in treating and preventing the infection of Acinetobacter baumannii.

Abstract: The present invention discloses a novel engineered peptides P3T, P7T, P8T, P9T, P13T and P8_d1 of Seq ID No. 1 to combinations comprising one or more said peptides and compositions comprising one or more said peptides with pharmaceutically acceptable carriers and excipients and their use. The peptides and composition comprising said peptides induce autophagy by binding the protein GAPR-1 (?ve regulator of autophagy). Endogenously, GAPR-1 acts by tethering critical autophagy protein Beclin-1 (+ve regulator of autophagy) at the golgi and arrest autophagy. The peptide reported here binds GAPR-1 to free Beclin-1 and subsequently induce autophagy. The peptide can be used to induce or enhance autophagy and finds therapeutic application in a broad spectrum of disease pathologies that benefit from augmented autophagy, including obesity, diabetes, NASH, cancer, cardiomyopathy, neurodegenerative diseases, IBD and pathogenic infections.

Abstract: Therapeutic Agents, Pharmaceutical Compositions, and Associated Biomarkers The invention relates to the identification of pharmaceutical compositions, therapeutic agents, peptides, nucleic acids, genetic constructs, vectors, cells, and medicaments, and their use in methods of treatment. For example, the treatment of neuropathological conditions, in particular Alzheimer's disease. Furthermore, provided herein are biomarkers, methods for their use, methods of diagnosis, methods of monitoring disease progression, and methods for monitoring medicament efficacy, in particular for Alzheimer's disease.

Abstract: Disclosed are pharmaceutical or cosmetic compositions comprising secretomes, for example secreted proteins from stem cells, and uses thereof. A composition that contains a secretome and an acceptable excipient may be free of a cell. The compositions are useful for inducing an immune response, treating an inflammatory response, treating a microbial infection, differentiating cells, wound healing, embryonic development, placental development, central nervous system development, or morphogenesis.

Abstract: The application provides new compositions and methods for stimulating the production of natural killer (NK) cells in a subject. NK cells can be selectively expanded with a combination of stimulating ligands. Methods and compositions for the administration of stimulatory ligands modified to self-insert into tumor cells, thereby stimulating an increase in the number of NK cells in proximity to a tumor, are also described.

Abstract: The present invention provides compositions and methods comprising an activator of IL-18 activity for use in therapeutic and non-therapeutic applications. The activator provides IL-18 signaling activity even in the presence of an inhibitory molecule such as IL-18BP.